Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy

Abstract Background & objective “Anti-angiogenetic drugs plus chemotherapy” (anti-angio-chemo) and “immune checkpoint inhibitors plus chemotherapy” (ICI-chemo) are superior to traditional chemotherapy in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). Howev...

Full description

Bibliographic Details
Main Authors: Lan-Lan Pang, Jia-Di Gan, Yi-Hua Huang, Jun Liao, Wei-Tao Zhuang, Wael-Abdullah-Sultan Ali, Shao-Dong Hong, Li Zhang, Wen-Feng Fang
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
Non-small cell lung cancer
Immunotherapy
Chemotherapy
Combination
Antiangiogenic agents
Meta-analysis
Online Access:https://doi.org/10.1186/s12885-022-10446-1

Similar Items

Similar Items